About Waiv
Waiv is a Paris-based AI precision oncology company, spun out of Owkin, that turns routinely generated digital histopathology and multimodal clinical data into AI-native precision tests for biomarker discovery, detection, and treatment-response assessment. Its clinical-grade products — including RlapsRisk BC, MSIntuit Suite, and BRCAura — support laboratories, clinicians, and pharmaceutical developers in improving patient stratification and accelerating cancer care decisions.
Company details
Funding
Total raised
$33M
Last stage
Series A
Investors
Founders
Meriem Sefta
CEO and Co-Founder of Waiv (formerly Owkin Dx), a Paris-based AI precision oncology testing company spun out of Owkin. Previously led the Owkin Dx division at Owkin.
LinkedInLionel Guillou
Co-Founder of Waiv (formerly Owkin Dx), previously part of the Owkin Dx team within Owkin.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.